 Clinical-stage immunotherapy company Nantkwest Inc NASDAQ: NK reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday. What Happened: Nantkwest said that early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled that of the historical rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists. 